Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction

• Published in: Journal of the American College of Cardiology Vol. 44; no. 10; pp. 1970 - 1976
• Main Authors: Ueland, Thor, Jemtland, Rune, Godang, Kristin, Kjekshus, John, Hognestad, Aina, Omland, Torbjørn, Squire, Iain B., Gullestad, Lars, Bollerslev, Jens, Dickstein, Kenneth, Aukrust, Pål
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 16.11.2004; Elsevier Limited
• Subjects: Aged; Cardiology; Cardiovascular disease; Case-Control Studies; Drug therapy; Female; Glycoproteins - blood; Heart attacks; Humans; Longitudinal Studies; Male; Middle Aged; Mortality; Myocardial Infarction - blood; Myocardial Infarction - diagnosis; Myocardial Infarction - mortality; Osteoprotegerin; Predictive Value of Tests; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear - blood; Receptors, Tumor Necrosis Factor - blood; Sensitivity and Specificity; Survival Analysis; RANKL; N-BNP; OPG; hsCRP; LVEF; OPTIMAAL; AMI; TNF; HF
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2004.06.076

We sought to determine the relationship between osteoprotegerin (OPG) and clinical outcomes in patients with heart failure (HF) after acute myocardial infarction (AMI). Arterial calcification is a prominent feature of arterial atherosclerosis and is associated with the occurrence of AMI. Osteoprotegerin is a recently discovered member of the tumor necrosis superfamily that may link the skeletal with the vascular system. We assayed plasma OPG levels in 234 patients with AMI complicated with HF and their relation to adverse outcomes during follow-up in patients randomly assigned to angiotensin-converting enzyme inhibition or angiotensin II antagonism. Blood was sampled at baseline (median three days after AMI), one month, and at one and two years. Elevated plasma levels of OPG at baseline were associated with adverse outcomes during a median of 27 months follow-up; OPG remained an independent prognostic indicator also after adjustment for other known predictors of mortality and cardiovascular events after AMI (e.g., creatinine clearance, N-terminal B-type natriuretic peptide, high-sensitivity C-reactive protein). In non-survivors, plasma OPG levels were persistently elevated during longitudinal testing, suggesting that OPG may be of value for monitoring patients at risk. Osteoprotegerin is a novel marker for cardiovascular mortality and clinical events in patients with AMI complicated with HF. These findings are compatible with the hypothesis suggesting a possible association between mediators of bone homeostasis and cardiovascular disease.